Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | ESR1 | P03372 | 3/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.54 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL223267 | 0.98 | LTA4H (0.62) | LTA4HESR1ESR2LTB4RLTB4R2 | |
| SCHEMBL25377781 | 0.83 | HRH3 (0.62) | LTA4HLTB4RLTB4R2PLA2G4B | |
| SCHEMBL2741668 | 0.81 | ESR1 (0.64) | LTA4HESR1ESR2MCHR1PLA2G4B | |
| SCHEMBL9936830 | 0.81 | LTA4H (0.67) | LTA4HESR1ESR2MCHR1MMP1 | |
| Hydrochloric Acid SCHEMBL224473 | 0.80 | ESR1 (0.62) | LTA4HESR1ESR2MCHR1PLA2G4B | |
| SCHEMBL4212893 | 0.80 | CYP1A2 (0.63) | LTA4HLTB4RLTB4R2PLA2G4B | |
| SCHEMBL11683055 | 0.80 | PLA2G4B (0.61) | LTB4RLTB4R2PLA2G4BALOX15TBXAS1 | |
| SCHEMBL3901613 | 0.80 | MAPK1 (0.66) | LTB4RLTB4R2PLA2G4BALOX15TBXAS1 | |
| SCHEMBL11684213 | 0.78 | PLA2G4B (0.69) | LTB4RLTB4R2PLA2G4BALOX15TBXAS1 | |
| SCHEMBL11063470 | 0.78 | LTA4H (0.52) | LTA4HESR1ESR2MCHR1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | LTA4H 3180/4885ESR1 1/4885ESR2 3/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | LTA4H 2984/4885ESR1 1/4885ESR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.